Clinical trials: Mucositis
Head and Neck Cancer
A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer
This is a Phase 1 / Phase 2 study of newly diagnosed patients with biopsy-proven head and neck cancer (squamous cell carcinoma) who are undergoing standard radiation therapy and treatment with cisplatin.
- Trial name
- BMX-HN (NCT02990468)
- Testing
- BMX-001, Radiation Therapy, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioMimetix JV, LLC
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
The purpose of this study is to determine the safety, tolerability, and the highest dose of GC4419 that can be given to patients with squamous cell cancer of the head and neck who are receiving standard radiation therapy and…
- Trial name
- NCT01921426
- Testing
- GC4419
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Galera Therapeutics, Inc.
Oral Mucositis
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
The purpose of the phase 3, clinical study is to determine if GC4419 (avasopasem manganese) administered prior to intensity-modulated radiation therapy (IMRT) reduces the severity of radiation induced oral mucositis in patients…
- Trial name
- NCT03689712
- Testing
- GC4419 90mg
- Where
- 97 sites in United States, Canada and 1 more
- Volunteers
- 455 people
- Sponsor
- Galera Therapeutics, Inc.
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum
Colon Cancer
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
The purpose of this study is to evaluate the efficacy, safety, and tolerability of palifermin (recombinant human keratinocyte growth factor, rHuKGF) in reducing the incidence of oral mucositis in subjects with stage 2B and 3…
- Trial name
- NCT00393822
- Testing
- palifermin
- Volunteers
- 100 people
- Sponsor
- Amgen
Head and Neck Cancer, Oral Mucositis (Ulcerative) Due to Radiation
Efficacy and Safety of CareMin650 for Prevention of Oral Mucositis in HNC Patients Starting Radiotherapy
Oral mucositis (OM) can affect up to 90% of head and neck cancer (HNC) patients treated with radiation therapy (RT). The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer and International…
- Conditions
- Head and Neck Cancer, Oral Mucositis (Ulcerative) Due to Radiation, Radiation Therapy Complication
- Trial name
- PrOMiSE (NCT04699487)
- Testing
- Photobiomodulation
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- NeoMedLight
Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome
Researchers want to learn more about the day-to-day use of Iberogast in people who have functional and motility-related gastrointestinal (stomach and bowel) diseases.
- Trial name
- NCT04993989
- Testing
- Iberogast (STW5, BAY98-7411)
- Where
- Germany
- Volunteers
- 843 people
- Sponsor
- Bayer
Stomatitis
Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant
CG53135-05, a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00104065
- Testing
- CG53135-05, velafermin
- Where
- 9 sites in United States
- Sponsor
- CuraGen Corporation
Peri-implant Mucositis
The Efficacy of Stabilized Chlorine Dioxide Rinse as a Chemical Adjuvant for Treatment of Per-implant Mucositis
A full understanding of etiology and diagnosis of peri-implant diseases is crucial for finding effective treatments for these diseases that are more widely accessible to dentists.
- Trial name
- NCT04838054
- Testing
- Stabilized chlorine dioxide oral rinse
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Rowpar Pharmaceuticals, Inc.
Oral Mucositis
Study for the Prevention of Oral Mucositis (SPOM)
1. Study Design Prospective, Randomized, Questionnaire-Based Study Study Type: Phase 1/Phase 2 Interventional Clinical Trial Intervention Model: Parallel Assignment Masking: None (Open-label) Actual Enrollment: 100 participants…
- Trial name
- SPOM (NCT05338398)
- Testing
- Bocaliner, Benzydamine
- Where
- Armenia
- Volunteers
- 100 people
- Sponsor
- E2Bio Life Sciences, LLC
Head and Neck Neoplasms, Mucositis
Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer
Oral Mucositis (OM) is a painful and debilitating side effect of many of the drug/radiation regimens used to treat cancer. This study examines the investigational drug brilacidin and its possible application in prevention of oral…
- Trial name
- Brilacidin (NCT02324335)
- Testing
- Brilacidin
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Oral Mucositis
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer
The purpose of this study is to determine whether an oral rinse composed of botanical extracts is effective in the prevention of severe inflammation of the lining of the oral cavity caused by chemotherapy and radiation therapy…
- Trial name
- NCT01400620
- Testing
- IZN-6N4
- Where
- 10 sites in United States, Israel
- Volunteers
- 110 people
- Sponsor
- Izun Pharma Ltd
Oral Mucositis
Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
Treatment for head and neck cancer often involves a combination of chemotherapy and radiation. One of the unfortunate consequences of standard care for head and neck cancer is the development of painful mouth sores, known as oral…
- Trial name
- NCT02542215
- Testing
- Cobiprostone, Standard Care - Chemotherapy, Standard Care - Radiation
- Where
- 76 sites in United States
- Volunteers
- 47 people
- Sponsor
- Sucampo Pharma Americas, LLC
Head and Neck Cancer, Oral Mucositis
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
The purpose of this study is to evaluate the efficacy and safety of SBG vs placebo on oral mucositis in head and neck cancer patients undergoing radiation therapy.
- Trial name
- NCT00790322
- Testing
- SBG
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Biotec Pharmacon ASA
Stomatitis
EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation
This is a Phase 2, randomized, double-blind, placebo-controlled, 2-stage trial in subjects with squamous cell cancers of the mouth, oropharynx, hypopharynx and nasopharynx planned to receive standard fractionated IMRT-delivered…
- Trial name
- NCT03200340
- Testing
- EC-18
- Where
- 20 sites in United States
- Volunteers
- 105 people
- Sponsor
- Enzychem Lifesciences Corporation
Oral Mucositis, Stem Cell Transplant Complications
Study of a New Medical Device for Oral Mucositis
This is a single-center randomized controlled trial of a new medical device (Bocaliner™) that has been designed to improve the treatment of chemotherapy-induced oral mucositis in patients undergoing cancer treatment.
- Trial name
- MDOM (NCT05104268)
- Testing
- Bocaliner
- Where
- Armenia
- Sponsor
- E2Bio Life Sciences, LLC
Oral Mucositis, Carcinoma in Situ of Upper Respiratory Tract
Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer
MUCIPLIQ is a nanopolymer engineered to mimic glycosaminoglycans such as heparan sulfates. Glycosaminoglycans are involved 1) in the stabilization of cells micro-environment, known as extracellular matrix, by binding to…
- Trial name
- MUCIPLIQ (NCT01840436)
- Testing
- MUCIPLIQ
- Where
- 5 sites in France
- Volunteers
- 136 people
- Sponsor
- Organ, Tissue, Regeneration, Repair and Replacement
Radiation Induced Oral Mucositis
A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer
The purpose of the phase 2, GT-201 clinical study is to determine if GC4419 administered prior to intensity-modulated radiation therapy (IMRT) reduces the incidence, duration, and severity of radiation induced oral mucositis in…
- Trial name
- NCT02508389
- Testing
- Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Intensity-Modulated Radiation Therapy
- Where
- 64 sites in United States, Canada and 1 more
- Volunteers
- 223 people
- Sponsor
- Galera Therapeutics, Inc.
Non-Small Cell Lung Cancer
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
To determine the optimal dose and schedule of Fusilev to prevent or reduce Folotyn-related Grade 3 or higher oral mucositis in patients with Non-Small Cell Lung Cancer.
- Trial name
- NCT01820091
- Testing
- Folotyn, Fusilev
- Sponsor
- Acrotech Biopharma Inc.